相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo et al.
BLOOD (2008)
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
E. Terpos et al.
LEUKEMIA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma:: A report from the GIMEMA -: Italian multiple myeloma network
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration
M. Teresa Cibeira et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
A Palumbo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
A Glasmacher et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cancer incidence and mortality in Europe, 2004
P Boyle et al.
ANNALS OF ONCOLOGY (2005)
The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma
R García-Sanz et al.
LEUKEMIA (2004)
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
P Tosi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
A Palumbo et al.
HEMATOLOGY JOURNAL (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
B Barlogie et al.
BLOOD (2001)
分享论文
